Brennan Doyle Email

V.P. - Head Investor Relations . BioXcel Therapeutics

Current Roles

Employees:
279
Revenue:
$43.2M
About
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.
BioXcel Therapeutics Address
555 Long Wharf Drive
New Haven, CT
United States
BioXcel Therapeutics Email

Past Companies

BioXcel Therapeutics, Inc.V.P. Investor Relations & Communications
EnkoChief Financial Officer
Guggenheim PartnersManaging Director, Healthcare Specialty Sales